Simplify access to TEPEZZA with Horizon Patient ServicesTM

When you are ready to prescribe, Horizon Patient Services is here to help

Horizon Patient Services offers a wide array of services for your patients and practice:

Horizon Patient Services icon Horizon Patient Services icon Horizon Patient Services icon

Patient support

  • Provide patient education about Thyroid Eye Disease (TED) and TEPEZZA
  • Support adherence by checking in with your patients prior to each infusion
Infusion logistics icon Infusion logistics icon Infusion logistics icon

Infusion logistics assistance

  • Provide options for a site of care for infusion (e.g., hospital outpatient department, physician office, independent infusion center, home)
  • Help schedule infusion appointments
Financial assistance icon Financial assistance icon Financial assistance icon

Financial assistance

  • Educate your patients about their insurance benefits
  • Help patients navigate their financial assistance options
Insurance benefits icon Insurance benefits icon Insurance benefits icon

Insurance benefits investigation

  • Assist in conducting insurance benefits investigations
  • Provide guidance for prior authorization, medical exception, or appeal process
  • Review coding and billing requirements

TEPEZZA Treatment Journey

Download the Treatment Journey to learn more about the process of initiating TEPEZZA and how Horizon Patient Services can help

Your Horizon Patient Services team

Reimbursement Access Specialists are your resource for navigating access and reimbursement

  • Your practice may need to complete several steps to obtain approval for TEPEZZA, including a benefits investigation to determine if prior authorization and/or medical exception are required
  • Your Reimbursement Access Specialist (RAS) can help you understand your patient’s benefits, support the completion of insurance approvals, and help resolve unique situations, such as denied claims
  • Your dedicated RAS has the local expertise to provide guidance to your practice

Patient Access Manager (PAM)

  • Coordinates care and provides personalized one-on-one support to your patients—from treatment initiation through completion

Getting started

Start patients off on the right track with their TEPEZZA treatment

1. ENROLL

If TEPEZZA is right for your patient, simply complete and submit the Patient Enrollment Form. For your convenience, there are two ways to complete and submit the Patient Enrollment Form:

Patient Enrollment Form

Download the form, complete it with your patient, including HCP signature, and submit by fax or email

DocuSign® Patient Enrollment Form

Access the form and complete it entirely online with HCP e-signature

What happens next:

  • Within 1 business day: Your patient will receive a welcome phone call from their dedicated PAM
  • Within 2 business days: You will receive a comprehensive summary of your patient’s benefits and contact information for your local RAS

2. COORDINATE

Your RAS will work with you to help simplify treatment initiation

3. PREPARE

The PAM will help prepare your patient for their infusions and provide ongoing support

4. FOLLOW UP

The PAM will reach out to your patient after each infusion to make sure everything went smoothly

Horizon Patient Services brochure

For more information, download the Horizon Patient Services brochure
Financial assistance icon Financial assistance icon

Financial assistance

Learn about assistance options for TEPEZZA available for your patients

INDICATION AND IMPORTANT SAFETY INFORMATION

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Infusion Reactions: TEPEZZA may cause infusion reactions. Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA. Reported infusion reactions have usually been mild or moderate in severity. Signs and symptoms may include transient increases in blood pressure, feeling hot, tachycardia, dyspnea, headache, and muscular pain. Infusion reactions may occur during an infusion or within 1.5 hours after an infusion. In patients who experience an infusion reaction, consideration should be given to premedicating with an antihistamine, antipyretic, or corticosteroid and/or administering all subsequent infusions at a slower infusion rate.

Preexisting Inflammatory Bowel Disease: TEPEZZA may cause an exacerbation of preexisting inflammatory bowel disease (IBD). Monitor patients with IBD for flare of disease. If IBD exacerbation is suspected, consider discontinuation of TEPEZZA.

Hyperglycemia: Increased blood glucose or hyperglycemia may occur in patients treated with TEPEZZA. In clinical trials, 10% of patients (two-thirds of whom had preexisting diabetes or impaired glucose tolerance) experienced hyperglycemia. Hyperglycemic events should be managed with medications for glycemic control, if necessary. Monitor patients for elevated blood glucose and symptoms of hyperglycemia while on treatment with TEPEZZA. Patients with preexisting diabetes should be under appropriate glycemic control before receiving TEPEZZA.

Adverse Reactions

The most common adverse reactions (incidence ≥5% and greater than placebo) are muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, dysgeusia, headache, and dry skin.

INDICATION

TEPEZZA is indicated for the treatment of Thyroid Eye Disease.

Please see Full Prescribing Information for more information.

INDICATION AND IMPORTANT SAFETY INFORMATION

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Infusion Reactions: TEPEZZA may cause infusion reactions. Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA. Reported infusion reactions have usually been mild or moderate in severity. Signs and symptoms may include transient increases in blood pressure, feeling hot, tachycardia, dyspnea, headache, and muscular pain. Infusion reactions may occur during an infusion or within 1.5 hours after an infusion. In patients who experience an infusion reaction, consideration should be given to premedicating with an antihistamine, antipyretic, or corticosteroid and/or administering all subsequent infusions at a slower infusion rate.

Preexisting Inflammatory Bowel Disease: TEPEZZA may cause an exacerbation of preexisting inflammatory bowel disease (IBD). Monitor patients with IBD for flare of disease. If IBD exacerbation is suspected, consider discontinuation of TEPEZZA.

Hyperglycemia: Increased blood glucose or hyperglycemia may occur in patients treated with TEPEZZA. In clinical trials, 10% of patients (two-thirds of whom had preexisting diabetes or impaired glucose tolerance) experienced hyperglycemia. Hyperglycemic events should be managed with medications for glycemic control, if necessary. Monitor patients for elevated blood glucose and symptoms of hyperglycemia while on treatment with TEPEZZA. Patients with preexisting diabetes should be under appropriate glycemic control before receiving TEPEZZA.

Adverse Reactions

The most common adverse reactions (incidence ≥5% and greater than placebo) are muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, dysgeusia, headache, and dry skin.

INDICATION

TEPEZZA is indicated for the treatment of Thyroid Eye Disease.

Please see Full Prescribing Information for more information.